Category - Markets

Maxim Group lowered its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $7 from $17, citing market environment, catalysts related to clients for Stellar’s Keyhole Limpet Hemocyanin (KLH) protein, revisions to...

Maxim Group downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target for the stock, which was quoted at $5.16, down $2.20, or 30% in trading Monday afternoon. The move...

Feltl & Co. upgraded Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) to “strong buy” from “buy” after the company posted second quarter revenue ahead of expectations yesterday on the strength of its direct sales...

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) reported revenue of $20.1-million in the second quarter, an increase of 34% from $15.1-million a year ago. Total direct sales in the latest quarter increased by $4.4-million...

BTIG Research downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy.” The stock closed at $9.05 on Tuesday. Analyst Dr. Sean Lavin writes that second quarter results were largely in-line. “The base business...

Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60...

Maxim Group cut its price target for “buy-rated” Celsion (NYSE:CLSN) to $4 from $9. The stock was quoted at $1.22 Friday afternoon. “While we are believers in Celsion’s ThermoDox product and platform, we recognize that...

H.C. Wainwright analyst Shaunak Deepak assumed coverage of Vical (NASDAQ:VICL) with a “buy” rating and $12 price target. The stock was quoted at $4.39, up 3 cents, Tuesday afternoon. “With a co-marketable asset in Phase...

Canaccord Genuity initiated coverage of Merit Medical Systems (NASDAQ:MMSI) with a “buy” rating and $27 price target. The stock closed at $20.51 on Monday. Merit develops, manufactures, and commercializes a vast array...

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday. “Selecta’s SVP-Rapamycin technology has the potential to open the doors of...